Patents by Inventor Andrew J. Bett
Andrew J. Bett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11911453Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.Type: GrantFiled: January 28, 2019Date of Patent: February 27, 2024Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Andrew J. Bett, Pedro Cejas, Lan Zhang, Christine Shaw
-
Publication number: 20230390379Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: May 10, 2023Publication date: December 7, 2023Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
-
Patent number: 11752206Abstract: Herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.Type: GrantFiled: March 15, 2018Date of Patent: September 12, 2023Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro, Dai Wang, Lan Zhang
-
Publication number: 20230270850Abstract: The present disclosure provides, among other things, a pharmaceutical composition that includes a lipid nanoparticle adjuvant and an anti-human papillomavirus (HPV) comprising HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.Type: ApplicationFiled: March 10, 2023Publication date: August 31, 2023Applicant: Merck Sharp & Dohme LLCInventors: Andrew J. Bett, John P. Bilello, Amy S. Espeseth, Tong-Ming Fu, Marian E. Gindy
-
Patent number: 11638754Abstract: The present disclosure provides, among other things, a pharmaceutical composition that includes a lipid nanoparticle adjuvant and an anti-human papillomavirus (HPV) comprising HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.Type: GrantFiled: February 9, 2021Date of Patent: May 2, 2023Assignee: Merck Sharp & Dohme LLCInventors: Andrew J. Bett, John P. Bilello, Amy S. Espeseth, Tong-Ming Fu, Marian E. Gindy
-
Publication number: 20230123584Abstract: The present disclosure provides, among other things, a pharmaceutical composition that includes a lipid nanoparticle adjuvant and an anti-human papillomavirus (HPV) comprising HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.Type: ApplicationFiled: February 9, 2021Publication date: April 20, 2023Applicant: Merck Sharp & Dohme LLCInventors: Marian E. Gindy, John P. Bilello, Amy S. Espeseth, Andrew J. Bett, Tong-Ming Fu
-
Publication number: 20230114180Abstract: The disclosure relates to respiratory syncytial vims (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: August 30, 2022Publication date: April 13, 2023Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
-
Patent number: 11464848Abstract: The disclosure describes respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: GrantFiled: March 15, 2018Date of Patent: October 11, 2022Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
-
Publication number: 20210338804Abstract: The present disclosure provides Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) vaccines, recombinant vesicular stomatitis virus (VSV) vectors encoding the SARS-CoV-2 spike (S) protein or an immunogenic variant thereof, recombinant replicable VSV particles having a SARS-CoV-2 S protein or an immunogenic variant thereof on the surface of the particles, and immunogenic recombinant proteins comprising a SARS-CoV-2 S protein or a variant thereof. Immunogenic compositions comprising the SARS-CoV-2 vaccines, the recombinant VSV vectors, the recombinant replicable VSV particles and/or the immunogenic recombinant proteins may be used for inducing an immune response to the SARS-CoV-2, preventing infection by the SARS-CoV-2, vaccinating against the SARS-CoV-2 and/or producing adaptive mutants of the recombinant replicable VSV particles.Type: ApplicationFiled: February 19, 2021Publication date: November 4, 2021Applicants: International AIDS Vaccine Initiative Inc., Merck Sharp & Dohme Corp.Inventors: Christopher Lee Parks, Maoli Yuan, Mark Feinberg, Amy Espeseth, Andrew J. Bett
-
Publication number: 20210252138Abstract: The present disclosure provides, among other things, a pharmaceutical composition that includes a lipid nanoparticle adjuvant and an anti-human papillomavirus (HPV) comprising HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.Type: ApplicationFiled: February 9, 2021Publication date: August 19, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Andrew J. Bett, John P. Bilello, Amy S. Espeseth, Tong-Ming Fu, Marian E. Gindy
-
Publication number: 20210046173Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.Type: ApplicationFiled: January 28, 2019Publication date: February 18, 2021Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Andrew J. Bett, Pedro Cejas, Lan Zhang, Christine Shaw
-
Publication number: 20200129615Abstract: The disclosure relates to herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.Type: ApplicationFiled: March 15, 2018Publication date: April 30, 2020Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro, Dai Wang, Lan Zhang
-
Publication number: 20200129608Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: March 15, 2018Publication date: April 30, 2020Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
-
Publication number: 20200054737Abstract: The disclosure relates to herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: April 25, 2018Publication date: February 20, 2020Applicant: Modema TX, Inc.Inventors: Giuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro, Dai Wang, Lan Zhang
-
Patent number: 10137187Abstract: The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent immune responses. In preferred embodiments of the compositions described herein, the DEN4 protein component is a dimeric form of DEN4. The compositions are designed to be acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. Also provided herein are methods of inducing a protective immune response in a human patient population by administering the compositions described herein to the patients.Type: GrantFiled: September 22, 2015Date of Patent: November 27, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Beth-Ann Griswold Coller, Vidya B. Pai, Jr., D. Elliot Parks, Michele Yelmene, Andrew J. Bett, Timothy Martyak
-
Publication number: 20180303929Abstract: The disclosure relates to herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: October 21, 2016Publication date: October 25, 2018Applicant: Moderna TX, Inc.Inventors: Giuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro
-
Publication number: 20180271970Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: October 21, 2016Publication date: September 27, 2018Applicant: ModernaTX, INC.Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
-
Publication number: 20160074502Abstract: The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent immune responses. In preferred embodiments of the compositions described herein, the DEN4 protein component is a dimeric form of DEN4. The compositions are designed to be acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. Also provided herein are methods of inducing a protective immune response in a human patient population by administering the compositions described herein to the patients.Type: ApplicationFiled: September 22, 2015Publication date: March 17, 2016Inventors: Beth-Ann Griswold Coller, Vidya B. Pai, D. Elliot Parks, Michele Yelmene, Andrew J. Bett, Timothy Martyak
-
Patent number: 9198964Abstract: The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent immune responses. In preferred embodiments of the compositions described herein, the DEN4 protein component is a dimeric form of DEN4. The compositions are designed to be acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. Also provided herein are methods of inducing a protective immune response in a human patient population by administering the compositions described herein to the patients.Type: GrantFiled: October 27, 2011Date of Patent: December 1, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Beth-Ann Griswold Coller, Vidya B. Pai, D. Elliot Parks, Michele Yelmene, Andrew J. Bett, Timothy Martyak
-
Patent number: 8889138Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: GrantFiled: October 11, 2010Date of Patent: November 18, 2014Assignees: Merck Sharp & Dohme Corp., Northwestern UniversityInventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Elizabeth Chen Dodson, Gene Kinney, William L Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola, Lei Chang